Vector Labs is closed to observe Independence Day (US Holiday) on Thursday, July 4th.
We will be back in the office on Friday. We will respond to emails upon our return. Have a wonderful day.

Mike Morales Joins Vector Laboratories as Chief Financial Officer

BURLINGAME, Calif.
December 14, 2021

Mr. Morales’ decades of financial experience in the life sciences sector will drive Vector Laboratories’ ongoing expansion strategy

Vector Laboratories, the pioneer and leader in the development and manufacture of protein labeling and detection reagents for life sciences research, today announced that Mike Morales, CPA, has joined the Executive Team as Chief Financial Officer, effective as of Monday, December 6.

Mr. Morales has 25 years of experience in financial management and public accounting, with nearly 20 of those years in the life sciences sector. He joins Vector Laboratories from Sony Biotechnology, a wholly owned subsidiary of Sony, where he led the Finance and Operations teams. He spent nearly 16 years at Amgen, where he held positions of increased responsibility. He also held positions at Kite Pharma, Avery Dennison, General Motors, and Ernst & Young, LLP. In his role at Vector Laboratories, he will accelerate the company’s vision to expand into protein detection through strategic acquisitions.

“Mike’s extensive experience with handling the unique financial needs of a life sciences-focused company makes him a great addition to the Vector Laboratories Executive Team,” said Dr. Lisa V. Sellers, CEO of Vector Laboratories. “This is another positive step we are taking to building a strong leadership team that will continue to expand our commercial footprint through acquisitions — we’re excited to see what we can accomplish together.”

“This is an exciting time to join Vector Laboratories as it embarks on this new phase of internal and external expansion” added Mr. Morales.“ I am looking forward to supporting Lisa and the rest of the Executive Team by providing the financial leadership needed to drive Vector’s growth strategies.”

The Vector Laboratories Executive Team also includes Dr. Pamela James, PhD, as the Vice President, Product, and the company will continue to add new members to implement the acquisition and development strategy. As the first company to commercialize avidin-biotin enzyme complex kits for immunohistochemistry and antifade mounting media for immunofluorescence, Vector Laboratories has since introduced over 600 reliable reagents and kits through four decades of leadership in labeling and detection technologies.

About Vector Laboratories

Vector Laboratories empowers scientific advances with innovative proteomic and glycomic solutions. Supporting industries worldwide for 45 years and counting, Vector Laboratories is a trusted manufacturing partner with unmatched technical expertise and a culture of service. Customers rely on Vector Laboratories’ immunofluorescence, immunohistochemistry, glycobiology and bioconjugation products and custom manufacturing capabilities to move science forward, with impact. Vector Laboratories’ market-tested product portfolio provides the critical tools researchers need to precisely visualize and study tissues and cells, and to ultimately tackle today’s biggest healthcare challenges. The company’s products and technologies have been cited in more than 350,000 peer-reviewed publications and its catalog and custom products are relied upon by laboratories around the world. Headquartered in Newark, CA, Vector Laboratories includes a global network of more than 40 distributors. For more information about Vector Laboratories, please visit: www.vectorlabs.com.

Contacts for the media: